NASD · Healthcare · Medical Instruments & Supplies · USA
Repligen Corp is a large cap company (market value between $10 billion and $200 billion) in the Medical Instruments & Supplies industry.
Repligen develops and commercializes bioprocessing technologies and systems for manufacturing biological drugs. The company serves biopharmaceutical companies, contract development and manufacturing organizations, and life science integrators through four main product franchises: Filtration, Chromatography, Process Analytics, and Proteins. Its operations span multiple manufacturing sites across the United States and Europe, with headquarters in Massachusetts.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Repligen Corp stock.
Overvalued: intrinsic value $24.96 per share, market price $176.43, margin of safety -606.7% (as of 2026-10-19).
Discounting its cash flows at 10.2% (average of 3 methods) values the shares at $24.96; the price of $176.43 is 607% above that value, and 73% of that value comes from beyond year five.
Leak Score: 40/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 50 Medical Instruments & Supplies stocks
20 more in this industry show a wider margin of safety.
RGEN is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.2% (average of 3 methods) values the shares at $24.96; the price of $176.43 is 607% above that value, and 73% of that value comes from beyond year five.
$24.96 per share (as of the 2026-10-19 close), against a market price of $176.43. That is a margin of safety of -606.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
40 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.